Pt-coated FeMOF nano-enzyme loaded frozen gel dressing and preparation method and application thereof

By loading Pt@FeMOF nanoenzyme in medical dressings, the problems of insufficient antibacterial performance and poor hemostasis performance of existing dressings are solved, and the effects of antibacterial, provascular repair and rapid hemostasis are achieved, which significantly improves the diabetic wound surface healing effect.

CN118987316APending Publication Date: 2024-11-22SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202411134165.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-19
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing medical dressings lack bioactivity in wound treatment, lack of antibacterial properties, and unstable loaded bioactive ingredients, which can easily lead to drug-resistant bacteria problems, and small pore size of the hydrogel leads to poor hemostatic performance.

Method used

Using frozen GelMA gel dressing with Pt@FeMOF nanozyme loading, FeMOF structure was formed under weak alkaline conditions through FeSO4·7H2O and phenylatic acid, and in situ reduction was carried out in situ to prepare Pt@FeMOF nanoparticles, and Mixed in GelMA, frozen gel dressings with multienzyme activity were prepared by frozen enlargement of pore size and ultraviolet cross-linking.

Benefits of technology

It has achieved the functions of wide antibacterial spectrum, high biocompatibility, promoting vascular repair and rapid hemostasis, and can adapt to the microenvironment of diabetic wounds, remove drug-resistant bacteria and delay endothelial cell aging, significantly improving the wound healing effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987316A_ABST
    Figure CN118987316A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of medical dressings, and particularly discloses a Pt-coated FeMOF nano-enzyme loaded frozen gel dressing as well as a preparation method and application of the Pt-coated FeMOF nano-enzyme loaded frozen gel dressing. The preparation method comprises the following steps: carrying out reaction on FeSO4. 7H2O and trimesic acid under a weak alkaline condition to form a FeMOF structure, then mixing a FeMOF solution with a chloroplatinic acid solution, and carrying out in-situ reduction on chloroplatinic acid by using a reducing agent to prepare Pt-coated FeMOF nano-enzyme; and mixing the Pt-coated FeMOF nano solution with a GelMA solution, freezing to enlarge the pore size of a colloid, and carrying out photo-crosslinking and freeze-drying to obtain the frozen gel dressing loaded with the Pt-coated FeMOF nano enzyme. The Pt-coated FeMOF nano-enzyme particles prepared by the method have multi-enzyme activity, can effectively remove drug-resistant bacteria and biological membranes and promote angiogenesis, and the large-aperture gel dressing can remarkably improve the hemostatic performance, so that the dressing can effectively accelerate the repair of infectious diabetes wound surfaces.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of medical dressings, and in particular to a Pt@FeMOF nanozyme-loaded cryogel dressing having both antibacterial and angiogenesis-promoting properties, and a preparation method and application thereof. Background Art

[0002] Traditional dressings such as dry gauze, oil gauze, cotton pads, and bandages are currently the most commonly used dressings for wound treatment in clinical practice, but due to the lack of biological activity, poor moisture retention, tissue adhesion and other shortcomings, the treatment effect is not good. Hydrogel has become a new generation of wound dressing research and development materials due to its excellent water absorption and moisture retention properties and modifiability. Methacryloyl gelatin (GelMA) is a gelatin-modified photocurable hydrogel that has good biocompatibility, excellent molding properties and adjustable physical and chemical properties. It is widely used in tissue regeneration, drug delivery and other fields. Loading bioactive ingredients such as antibacterial and angiogenic in GelMA is the main way to give dressings multifunctionality and improve the wound healing treatment effect: angiogenic components specifically include stem cell exosomes, IL-8, peptide drugs, VH298, panthenol citrate, human adipose stem cells and platelet-rich plasma, hydrogen sulfide and other bioactive drugs. Antibacterial components specifically include antibiotics, antimicrobial peptides and bacteriophages.

[0003] However, there are three main limitations in improving the antibacterial and vascular repair-promoting properties of dressings by loading bioactive ingredients in GelMA hydrogels: first, the currently loaded bioactive ingredients are unstable and easily inactivated, which greatly increases the preparation and storage costs of dressings; second, antibiotic-based antibacterial substances accelerate antibiotic resistance and are ineffective against resistant bacteria; third, hydrogel dressings have a small pore size and insufficient hemostatic properties. Summary of the invention

[0004] In view of the deficiencies of the prior art, the purpose of the present invention is to provide a medical dressing with a broad antibacterial spectrum, high biocompatibility, strong antibacterial performance, and the function of promoting vascular repair and rapid hemostasis, as well as its preparation method and application. The dressing is a frozen GelMA loaded with Pt@FeMOF nanozyme. The cryogel technology makes GelMA have a larger pore size and improves its hemostatic performance. In the infection microenvironment, the Pt@FeMOF nanozyme exerts its peroxidase activity and produces hydroxyl radicals to remove drug-resistant bacteria. In addition, the Pt@FeMOF nanozyme has catalase activity under neutral conditions, which delays endothelial cell aging, improves endothelial cell function, and accelerates vascular repair by removing ROS inside and outside endothelial cells. Finally, the healing of infectious diabetic wounds is achieved.

[0005] In order to achieve the above object, the specific technical solution adopted by the present invention is as follows:

[0006] In a first aspect, the present invention provides a method for preparing a cryogel dressing loaded with Pt@FeMOF nanozyme, comprising the following steps:

[0007] (1) Preparation of Pt@FeMOF nanozyme: FeSO4·7H2O and trimesic acid react under alkaline conditions to form a FeMOF structure; then the FeMOF solution is mixed with a chloroplatinic acid solution, and the chloroplatinic acid is in situ reduced using a reducing agent to prepare Pt@FeMOF nanoparticles;

[0008] (2) Preparation of frozen GelMA gel: Add the prepared Pt@FeMOF nano solution into the GelMA solution and mix them evenly; first freeze the mixed solution to expand the colloidal pore size; then use ultraviolet light to perform photocrosslinking; after the photocrosslinking is completed, freeze-dry to obtain a frozen gel dressing loaded with Pt@FeMOF nanozyme.

[0009] Furthermore, in step (1), the FeSO4·7H2O and trimesic acid are stirred at room temperature for 12 to 14 hours under weak alkaline conditions to form a FeMOF structure. The preparation process is carried out under weak alkaline conditions (about pH 8.5) to enhance the solubility of metal ions, promote the coordination of metal ions, and improve the stability of MOF materials. Too high or too low pH will not only reduce the reaction rate of the reactants but also make them easy to decompose, which is not conducive to the formation of the MOF material structure.

[0010] Furthermore, in step (1), the reducing agent is sodium borohydride, which is dissolved in methanol before use. Methanol mainly plays the following roles: first, as a solvent, it dissolves metal salts and ligands and promotes the synthesis of MOF materials. Second, it can be used as a catalyst carrier in MOF materials to increase the loading amount and catalytic activity of platinum nanoparticle catalysts. In addition, using methanol to disperse Pt@FeMOF nanoparticles is not easy to destroy the MOF structure.

[0011] Furthermore, in step (2), the concentration of Pt@FeMOF nanozyme in the mixed solution is no more than 0.5 mg ml -1 , avoiding agglomeration in the hydrogel and causing uneven dispersion.

[0012] Furthermore, in step (2), the mixed solution is frozen under the following conditions: a temperature of -80 to -15°C, outside which ice crystals cannot form to enlarge the pore size, and the freezing time is 0.5 to 6 hours.

[0013] Furthermore, in step (2), the photo-crosslinking time is 5 to 10 minutes. If the time is too short, crosslinking may not be possible, and if the time is too long, hardening may occur.

[0014] Furthermore, in step (2), the freeze-drying conditions are: temperature -60 to -10°C, time 12 to 24 hours.

[0015] In a second aspect, the present invention provides a cryogel dressing loaded with Pt@FeMOF nanozyme prepared by the above-mentioned preparation method.

[0016] In a third aspect, the present invention provides the use of a cryogel dressing loaded with Pt@FeMOF nanozyme prepared by the above-mentioned preparation method in accelerating the healing of infectious diabetic wounds.

[0017] Specifically, the dressing of the present invention includes Pt@FeMOF nanozyme and frozen GelMA gel. The Pt@FeMOF nanozyme is prepared by reacting FeSO4·7H2O and trimesic acid under weak alkaline conditions to form a FeMOF structure, and then mixing a chloroplatinic acid solution with it and reducing it in situ. The prepared Pt@FeMOF nanozyme particles have multi-enzyme activity. Under acidic conditions, the nanozyme exhibits peroxidase activity, catalyzing hydrogen peroxide to produce highly toxic hydroxyl radicals, effectively removing drug-resistant bacteria and biofilms; and after the infection ends, with the change of the pH of the microenvironment, the nanozyme exhibits catalase activity, targetedly removing ROS, inhibiting endothelial cell aging, and promoting angiogenesis. The frozen GelMA gel is prepared by mixing the Pt@FeMOF nano solution with the GelMA solution and freezing it to expand the pore size of the colloid, and then using ultraviolet light cross-linking. With the same gelling material and under the same conditions, the cryogel dressing of the present invention is larger than the hydrogel dressing. The pore size of the present invention is about twice that of the hydrogel dressing. The large-pore gel dressing can significantly improve the hemostatic performance. At the same time, the gel acts as a carrier to absorb wound exudate and release active nanoenzyme components, ultimately accelerating the repair of infectious diabetic wounds through antibacterial, angiogenic and hemostatic effects.

[0018] The present invention has the following beneficial effects:

[0019] 1. The gelling material gelatin selected in the present invention is a natural high molecular compound obtained by processing collagen in animal tissues. It has excellent biocompatibility and degradability, is easily absorbed by tissues, and its large pore size after freezing treatment can significantly accelerate wound hemostasis and exudate absorption.

[0020] 2. The nanozyme prepared by the present invention can adapt to the diabetic wound microenvironment, exhibit antibacterial activity through peroxidase under infection conditions, and exhibit catalase activity in the late stage of wound healing, improve angiogenesis function by inhibiting endothelial cell aging, and accelerate diabetic wound repair.

[0021] 3. The preparation method of the dressing for promoting wound repair of the present invention is simple. The Pt@FeMOF nanozyme can be prepared at room temperature without harsh reaction conditions such as high temperature and high pressure, and is easy to control. Compared with conventional proteases, the biological activity of the nanozyme is not easily affected by the storage temperature and is more stable. Therefore, the dressing of the present invention is a good wound repair dressing.

[0022] 4. As of 2021, the number of diabetes patients in China has reached 141 million, with an incidence rate as high as 12.8%. If the dressing of the present invention can be widely used clinically, it will further improve the repair effect of diabetic wounds, which has important clinical significance and huge socioeconomic value. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 :Preparation flow chart of the cryogel dressing loaded with Pt@FeMOF nanozyme of the present invention. In the figure, A is the synthesis process of Pt@FeMOF nanozyme, and B is the preparation process of the cryogel dressing loaded with Pt@FeMOF nanozyme.

[0024] Figure 2 : Characterization test results of Pt@FeMOF nanozyme particles in Example 1 of the present invention. In the figure, A is a transmission electron microscopy image of FeMOF, B is a transmission electron microscopy image and element distribution results of Pt@FeMOF, C is the x-ray photoelectron spectroscopy results of FeMOF and Pt@FeMOF, and D is the X-ray diffraction results of FeMOF and Pt@FeMOF.

[0025] Figure 3 : Scanning electron micrograph of the cryogel in Example 1 of the present invention.

[0026] Figure 4 : Test results of the peroxidase activity of Pt@FeMOF nanozyme in Example 1 of the present invention. In the figure, A is the electron paramagnetic resonance (ESR) result, and B is the TMB result.

[0027] Figure 5 : Test results of the antibacterial activity of Pt@FeMOF nanozyme in Example 1 of the present invention. In the figure, A is the plate coating result of methicillin-resistant Staphylococcus aureus, B is the plate coating result of Pseudomonas aeruginosa, C is the crystal violet staining result of methicillin-resistant Staphylococcus aureus biofilm, and D is the crystal violet staining result of Pseudomonas aeruginosa biofilm.

[0028] Figure 6 : Test results of the angiogenesis activity of Pt@FeMOF nanoenzyme in Example 1 of the present invention. In the figure, A is the result of the tube formation experiment, B is the quantitative result of the tube formation experiment, C is the result of endothelial cell β-galactosidase staining, and D is the quantitative result of endothelial cell β-galactosidase staining.

[0029] Figure 7 : Verification results of the ability of the cryogel dressing loaded with Pt@FeMOF nanozyme to promote wound repair in Example 1 of the present invention. In the figure, A shows the healing status of diabetic wounds infected with methicillin-resistant Staphylococcus aureus over time, and B shows the healing status of diabetic wounds infected with Pseudomonas aeruginosa over time. DETAILED DESCRIPTION

[0030] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments.

[0031] Example 1

[0032] A cryogel dressing loaded with Pt@FeMOF nanozyme, according to Figure 1 The specific preparation method is as follows:

[0033] (1) Preparation of Pt@FeMOF nanozyme: FeSO4·7H2O and trimesic acid were stirred at room temperature for 12 h under weak alkaline conditions to form a FeMOF structure. 1 mL of FeMOF material solution was mixed with 0.25 mL of 10 mM chloroplatinic acid and stirred for 2 h to allow the MOF material to fully adsorb platinum ions. Then, 0.5 mL of 0.25 M sodium borohydride solution was added to the mixture and stirred for 1 hour (sodium borohydride was dissolved in methanol solution to prepare sodium borohydride solution, which was used within 5 to 10 min after preparation). The product was collected by centrifugation and washed with methanol three times, and the product was dispersed in methanol solution for further use to prepare Pt@FeMOF nanoparticles.

[0034] (2) Preparation of frozen GelMA gel: Add the prepared Pt@FeMOF nanoparticle solution to the GelMA solution and mix well. The final concentration of the nanomaterial should not exceed 0.5 mg ml -1 The mixed solution was first frozen at -20 for 30 minutes to expand the pore size of the colloid; then photocrosslinked using ultraviolet light for 5 minutes; finally transferred to a freeze dryer and dried at -54°C for 24 hours.

[0035] The Pt@FeMOF nanozyme and dressing prepared in Example 1 were subjected to the following performance tests:

[0036] 1. Characterization Test

[0037] Test method: The morphology of Pt@FeMOF nanozyme particles and frozen GelMA gel was observed under a microscope, and the Pt@FeMOF nanozyme particles were tested by X-ray photoelectron spectroscopy (XPS) and X-ray diffraction (XRD).

[0038] Test results: Figure 2As shown in the figure, the morphology of Pt@FeMOF nanozyme particles presents a typical three-dimensional MOF structure. From the XPS and XRD results, it can be seen that Pt@FeMOF was successfully prepared on the basis of synthesizing FeMOF. XPS successfully detected the Pt element, and XRD showed that the introduction of Pt did not affect the crystal structure of FeMOF. Figure 3 As shown in Figure 3, the frozen GelMA gel (Pt@FeMOF-CG) is morphologically composed of a porous structure and has a larger pore size than the normal hydrogel (Pt@FeMOF-HG).

[0039] 2. Nanozyme peroxidase activity test

[0040] Test method: The catalytic activity of the prepared nanozyme was detected by electron paramagnetic resonance (ESR) and TMB oxidation experiments. Hydroxyl radicals appear as a peak with a height of 1:2:2:1 in the ESR results, and the higher the height, the more hydroxyl radicals are produced. When TMB encounters oxidizing substances, it changes from colorless to blue, and absorption peaks are formed at 380nm and 650nm. The height of the peak is proportional to the hydroxyl radicals produced.

[0041] Test results: Figure 4 As shown, it can be seen that the Pt@FeMOF nanozyme exhibits the highest 1:2:2:1 peak shape in the ESR results, and the highest absorbance at 380nm and 650nm, indicating that the Pt@FeMOF nanozyme has the strongest peroxidase activity.

[0042] 3. Antimicrobial Activity Test

[0043] Test method: The antibacterial effect of the synthesized nanozyme was evaluated by plate colony counting method; the anti-biofilm effect of the nanozyme was evaluated by crystal violet staining.

[0044] Test results: Figure 5 As shown, it can be seen that after Pt@FeMOF treatment, the colony numbers of both bacteria were significantly reduced, and the crystal violet staining depth also decreased significantly, indicating that Pt@FeMOF nanozyme has antibacterial activity against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa and their biofilms.

[0045] IV. Testing of angiogenic activity

[0046] Test method: The tube formation experiment was used to evaluate the vascular repair effect of the synthesized nanoenzyme. Endothelial cells were inoculated in matrix gel to observe the tube formation of endothelial cells, and β-galactosidase staining was used to observe the aging of endothelial cells.

[0047] Test results: Figure 6As shown, it can be seen that in the Pt@FeMOF nanozyme treatment group, the number of endothelial cell rings increased significantly, and the number of β-galactosidase-positive cells was significantly reduced, indicating that Pt@FeMOF nanozyme has pro-angiogenic activity and can delay endothelial cell aging.

[0048] 5. Experiment to verify the ability to promote wound repair

[0049] Test method: The prepared cryogel dressing loaded with Pt@FeMOF nanozyme was placed on the back wound of infected diabetic mice, and the wound healing was observed at 0, 3, 7, and 14 days. The untreated group (CTR), PBS treatment group, and cryogel treatment group were set as controls. Two types of diabetic wounds infected with methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa were tested according to this method.

[0050] Test results: Figure 7 As shown, it can be seen that the back wound area of ​​mice treated with Pt@FeMOF nanozyme on the 14th day was significantly reduced compared with the other three groups. The cryogel dressing loaded with Pt@FeMOF nanozyme can promote the repair of infectious diabetic wounds (methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa).

[0051] This specific implementation is only an explanation of the present invention, not a limitation of the present invention. Any changes made by those skilled in the art after reading the specification of the present invention will be protected by the patent law as long as they are within the scope of the claims of the present invention.

Claims

1. A method for preparing a cryogel dressing loaded with Pt@FeMOF nanozyme, It is characterized in that The following steps are involved: (1) Preparation of Pt@FeMOF nanozymes: using FeSO 4 7H 2 O and trimesic acid react under weak alkaline conditions to form a FeMOF structure; then the FeMOF solution is mixed with a chloroplatinic acid solution, and the chloroplatinic acid is in situ reduced using a reducing agent to prepare Pt@FeMOF nanoparticles; (2) Preparation of frozen GelMA gel: Add the prepared Pt@FeMOF nano solution into the GelMA solution and mix them evenly; first freeze the mixed solution to expand the colloidal pore size; then use ultraviolet light to perform photocrosslinking; after the photocrosslinking is completed, freeze-dry to obtain a frozen gel dressing loaded with Pt@FeMOF nanozyme.

2. The method for preparing the cryogel dressing loaded with Pt@FeMOF nanozyme according to claim 1, It is characterized in that In step (1), the FeSO 4 7H 2 O and trimesic acid are stirred at room temperature for 10 to 14 hours under weak alkaline conditions to form a FeMOF structure.

3. The method for preparing the cryogel dressing loaded with Pt@FeMOF nanozyme according to claim 1, It is characterized in that In step (1), the reducing agent is sodium borohydride, which is dissolved in methanol before use.

4. The method for preparing the cryogel dressing loaded with Pt@FeMOF nanozyme according to claim 1, Features: In step (2), the concentration of Pt@FeMOF nanozyme in the mixed solution does not exceed 0.5 mg ml -1 .

5. The method for preparing the cryogel dressing loaded with Pt@FeMOF nanozyme according to claim 1, Features: In step (2), the mixed solution is frozen under the following conditions: temperature -80 to -15°C and time 0.5 to 6 hours.

6. The method for preparing the cryogel dressing loaded with Pt@FeMOF nanozyme according to claim 1, Features: In step (2), the photo-crosslinking time is 5 to 10 minutes.

7. The method for preparing the cryogel dressing loaded with Pt@FeMOF nanozyme according to claim 1, Features: In step (2), the freeze-drying conditions are: temperature -60 to -10°C, time 12 to 24 hours.

8. A cryogel dressing loaded with Pt@FeMOF nanozyme prepared by the preparation method according to any one of claims 1 to 7.

9. Use of the Pt@FeMOF nanozyme-loaded cryogel dressing according to claim 8 in accelerating the healing of infectious diabetic wounds.

Citation Information

Cited By

  • Nano-composite hydrogel based on Mg-MOFs as well as preparation method and application of nano-composite hydrogel

    CN119405903A

  • Photo-thermal antibacterial hydrogel based on polydopamine-platinum nano composite material as well as preparation method and application of photo-thermal antibacterial hydrogel

    CN122321209A